Cardiovascular
Novo shells out $1.1bn to buy Cardior to expand cardiovascular pipeline
Novo Nordisk has agreed to acquire Germany-based Cardior Pharmaceuticals for up to €1bn ($1.1bn) to expand its cardiovascular pipeline. The…
FDA approves Wegovy for reducing risk of cardiovascular death
The US Food and Drug Administration (FDA) has approved a label update for Novo Nordisk’s glucagon-like peptide-1 receptor agonist (GLP-1RA)…
FDA approves Idorsia’s once-daily antihypertensive Tryvio
Switzerland-based Idorsia has received approval from the US Food and Drug Administration (FDA) for the use of Tryvio (aprocitentan) as…
Novo expands Wegovy’s US label to reduce cardiovascular events
The US Food and Drug Administration (FDA) has approved Novo Nordisk’s Wegovy (semaglutide) as a treatment to reduce the risk…
Novo Nordisk signs $1.46bn deal to develop molecular glue therapies
Novo Nordisk has signed a collaboration and licensing agreement with US-based biotech Neomorph to discover and develop multiple molecular glue…
United Therapeutics sues FDA over handling of Liquidia’s NDA
United Therapeutics has sued the US Food and Drug Administration (FDA), claiming the agency did not follow rules when approving…
CSL’s ‘big’ post-heart attack drug fails in Phase III trial
Australian CSL has released topline results from the Phase III AEGIS-II trial of CSL112 in patients following an acute myocardial…
Silence announces $120m private placement for depositary shares
Silence Therapeutics has announced an oversubscribed private placement of its 5,714,286 American depositary shares (ADS) priced at $21 each. The…
BridgeBio secures $1.25bn for genetic therapy development
BridgeBio Pharma has secured strategic financing of $1.25bn from Blue Owl Capital and the Canada Pension Plan Investment Board (CPP…
Comanche raises $75m to develop preeclampsia therapy
US-based Comanche Biopharma has raised $75m in an oversubscribed Series B financing round to develop its small interfering RNA (siRNA)…
